PRESCRIBE UBRELVY® TO TREAT MIGRAINE ATTACKS WHEN HEAD PAIN SPIKES
OR BEFORE IT STRIKES1

WHEN HEAD PAIN SPIKES

POWERFUL & RAPID

ELIMINATES PAIN1 — 21% of patients experienced pain freedom at 2 hours (co-primary endpoint).* UBRELVY 100 mg (95/448) vs 12% placebo (54/456)1,3

RELIEVES PAIN QUICKLY1 — 61% of patients experienced pain relief at 2 hours (secondary endpoint).* UBRELVY 100 mg (275/448) vs 49% placebo (224/456)1,4

BEFORE HEAD PAIN STRIKES

HEAD PAIN AVOIDANCE

UBRELVY is the FIRST AND ONLY acute treatment for migraine with demonstrated prodrome data in a phase 3 clinical trial5†

Data on patients who avoided moderate to severe headache pain when UBRELVY 100 mg was taken during prodrome5

CHOOSE SOMETHING DIFFERENT.
IT'S TIME TO START UBRELVY.

*In pivotal clinical studies, patients took UBRELVY within 4 hours of migraine headache onset.6

The prodrome study was a phase 3, multicenter, randomized, double-blind, placebo-controlled, crossover study in which the prodrome phase was defined as 1-6 hours prior to onset of headache.5 See prodrome study design pop-up for additional details.

Data presented above are in reference to UBRELVY 100 mg only. See similar results for patients taking UBRELVY 50 mg.7

See ACHIEVE pivotal trials design pop-up for more detail, including additional co-primary endpoint data.

Map of the United States with the number 56% in it

56% of commercially insured lives are unrestricted or require 0 or 1 prior therapy to access UBRELVY8‡§

More on national access
Location pin icon

Discover plans in your area that cover UBRELVY

More on local access
Ubrelvy Savings Card

With the UBRELVY Complete Savings Card, eligible commercially insured patients may pay as little as $0II per month for UBRELVY

Help patients save

Managed Markets Insight & Technology, LLCTM, a trademark of MMIT. Data as of January 2025 and subject to change.


Data are not a guarantee of coverage, or partial or full payment, by any payers listed. Actual benefits are determined by respective plan administrators. Insurer plans, coverage criteria, and formularies are subject to change without notice. Check each patient’s coverage with applicable insurer. AbbVie does not endorse any individual plans. Formulary coverage does not imply efficacy or safety.

§Unrestricted implies no step edit.

IIEligibility: Available to patients with commercial insurance coverage for UBRELVY who meet eligibility criteria. This co-pay assistance program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs), or where prohibited by law. Offer subject to change or termination without notice. Restrictions, including monthly maximums, may apply. This is not health insurance. For full Terms and Conditions, visit UBRELVY.com/savings-terms or call 1-844-482-7358 for additional information. To learn about AbbVie’s privacy practices and your privacy choices, visit https://abbv.ie/corpprivacy.

HEAR WHAT UBRELVY PATIENTS ARE SAYING
ABOUT THEIR TREATMENT EXPERIENCE